コンテンツへスキップ
Merck
  • Investigation of the therapeutic effectiveness of active components in Sini decoction by a comprehensive GC/LC-MS based metabolomics and network pharmacology approaches.

Investigation of the therapeutic effectiveness of active components in Sini decoction by a comprehensive GC/LC-MS based metabolomics and network pharmacology approaches.

Molecular bioSystems (2014-10-16)
Si Chen, Si Wu, Wuhong Li, Xiaofei Chen, Xin Dong, Guangguo Tan, Hai Zhang, Zhanying Hong, Zhenyu Zhu, Yifeng Chai
要旨

As a classical formula, Sini decoction (SND) has been fully proved to be clinically effective in treating doxorubicin (DOX)-induced cardiomyopathy. Current chemomics and pharmacology proved that the total alkaloids (TA), total gingerols (TG), total flavones and total saponins (TFS) are the major active ingredients of Aconitum carmichaelii, Zingiber officinale and Glycyrrhiza uralensis in SND respectively. Our animal experiments in this study demonstrated that the above active ingredients (TAGFS) were more effective than formulas formed by any one or two of the three individual components and nearly the same as SND. However, very little is known about the action mechanisms of TAGFS. Thus, this study aimed to use for the first time the combination of GC/LC-MS based metabolomics and network pharmacology for solving this problem. By metabolomics, it was found that TAGFS worked by regulating six primary pathways. Then, network pharmacology was applied to search for specific targets. 17 potential cardiovascular related targets were found through molecular docking, 11 of which were identified by references, which demonstrated the therapeutic effectiveness of TAGFS using network pharmacology. Among these targets, four targets, including phosphoinositide 3-kinase gamma, insulin receptor, ornithine aminotransferase and glucokinase, were involved in the TAGFS regulated pathways. Moreover, phosphoinositide 3-kinase gamma, insulin receptor and glucokinase were proved to be targets of active components in SND. In addition, our data indicated TA as the principal ingredient in the SND formula, whereas TG and TFS served as adjuvant ingredients. We therefore suggest that dissecting the mode of action of clinically effective formulae with the combination use of metabolomics and network pharmacology may be a good strategy.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
アセトン, ACS reagent, ≥99.5%
Sigma-Aldrich
アセトン, suitable for HPLC, ≥99.9%
Sigma-Aldrich
アセトン, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%
Sigma-Aldrich
ヘプタン, suitable for HPLC, ≥99%
Sigma-Aldrich
ピリジン, ACS reagent, ≥99.0%
Sigma-Aldrich
ヘプタン, ReagentPlus®, 99%
Sigma-Aldrich
アセトン, Laboratory Reagent, ≥99.5%
Sigma-Aldrich
ピリジン, suitable for HPLC, ≥99.9%
Sigma-Aldrich
ヘプタン, HPLC Plus, for HPLC, GC, and residue analysis, 99%
Sigma-Aldrich
アセトン, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.5% (GC)
Sigma-Aldrich
クロロトリメチルシラン, ≥98.0% (GC)
Sigma-Aldrich
ピリジン, ReagentPlus®, ≥99%
Sigma-Aldrich
ヘプタン, puriss. p.a., reag. Ph. Eur., ≥99% n-heptane basis (GC)
Sigma-Aldrich
アセトン, suitable for HPLC, ≥99.8%
Sigma-Aldrich
無水酢酸, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99% (GC)
Sigma-Aldrich
クロロトリメチルシラン, purified by redistillation, ≥99%
Sigma-Aldrich
アセトン, ACS reagent, ≥99.5%
Sigma-Aldrich
メトキシアミン 塩酸塩, 98%
USP
アセトン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
クレアチン, anhydrous
Sigma-Aldrich
アセトン, JIS special grade, ≥99.5%
Sigma-Aldrich
アセトン, histological grade, ≥99.5%
Sigma-Aldrich
無水酢酸, 99.5%
Sigma-Aldrich
アセトン, puriss., meets analytical specification of Ph. Eur., BP, NF, ≥99% (GC)
Sigma-Aldrich
ピリジン, ≥99%
Sigma-Aldrich
ピリジン, ACS reagent, ≥99.0%
Sigma-Aldrich
ピリジン, anhydrous, 99.8%
Sigma-Aldrich
無水酢酸, ReagentPlus®, ≥99%
Sigma-Aldrich
アセトン, natural, ≥97%
Sigma-Aldrich
ピリジン, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.5% (GC)